PNNL

Abstract

The NIAID-funded SSGCID is a consortium established to apply structural genomics approaches to potential drug targets from NIAID-priority infectious disease organisms. Management of SSGCID is overseen by a Scientific Leadership Team comprised of scientists at Seattle BioMed, Emerald BioStructures, the University of Washington and the Pacific Northwest National Laboratory. The mission of this consortium is to determine approximately 400 protein structures over a five-year period. Our target selection process engages the infectious disease research and drug therapy communities to identify drug targets, essential enzymes, virulence factors and vaccine candidates of biomedical relevance to combat infectious diseases. The resulting protein expression systems, purified proteins, ligand screens and protein structures produced by SSGCID provide a valuable data resource for the scientific community that will benefit future research and drug discovery. We present details of our high-throughput pipeline, interesting structure determination case stories and specifics of our services to the scientific community.